Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1819576 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $86.82Day +2.84%Mkt cap $7.7B1Y +338.0%Off 52W high −4.7%Vol (1Y) 67.2%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,008 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest13.9% of sh out |
| Days to cover9.2d |
| 13F net flow (QoQ)−0.13% |
| Top-10 13F concentration62.9% |
| Next report (est.)2026-08-08 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$288.1M |
| Earnings (TTM)$22.3M |
| ROE−111.1% |
| Net margin−43.5% |
| Sales growth 3Y115.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+151.7% |
| 1Y+338.0% |
| 3Y+1018.8% |
| 5Y+3443.7% |
| Since incept. (ann.)+29.3% |
Total return through 2026-07-28 · series begins 2018-07-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)67.2% |
| Ann. volatility (3Y)64.5% |
| Sharpe (1Y)2.57 |
| Sharpe (3Y)1.61 |
| Max drawdown (1Y)−35.7% |
| Max drawdown (3Y)−46.8% |
| Beta (3Y vs SPY)1.06 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 8.7M | $327M | 9.73% | +0.0% |
| Caligan Partners LP | 8.1M | $306M | 9.13% | +0.0% |
| BlackRock, Inc. | 5.5M | $207M | 6.17% | +0.0% |
| FINDELL CAPITAL MANAGEMENT LLC | 3.5M | $132M | 3.94% | +22.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.9M | $110M | 3.29% | new |
| Opaleye Management Inc. | 2.5M | $89M | 2.86% | +4.5% |
| BANK OF AMERICA CORP /DE/ | 2.3M | $86M | 2.57% | +18.7% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9M | $73M | 2.17% | +19.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | $0.52 | — | $132.9M | +4158.5% |
| 2025-12-31 | 2026-03-05 | — | — | $92.0M | +3054.6% |
| 2025-09-30 | 2025-11-03 | −$0.04 | — | $54.3M | +1121.7% |
| 2025-06-30 | 2025-08-12 | −$0.49 | — | $8.8M | +141.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-08 is ESTIMATED from filing cadence (median gap 89d) — not company-confirmed.
Single Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
